Robert Marcus
JPMorgan Chase & Co, Research Division
Good afternoon, everyone. I’m Robbie Marcus, the MedTech analyst at JPMorgan. Really happy to present Merit Medical. We have new CEO, Martha Aronson. Martha is going to give a presentation, and then we’ll do some Q&A after. Martha?
Martha Aronson
President, CEO & Director
Great. Well, thanks very much, Robbie, and thank you to JPMorgan for the opportunity today to speak to you all. Here’s our forward-looking statements as well as our non-GAAP financial measures. So let me start by just saying that I’m extremely excited to be here today as the new CEO of Merit Medical. I’m joined today also by Raul Parra, our CFO. Raul has been at Merit for about 16 years and has served as our CFO for the last 7.5 years.
So for those of you I haven’t had the chance to meet, again, my name is Martha Aronson, and I was appointed CEO on October 3, 2025, succeeding our company’s founder, Fred Lampropoulos. I’ve actually been in the industry for several decades now, having worked at Medtronic and Hill-Rom prior to the Baxter acquisition as well as the Ecolab Healthcare business. In addition, I served on a number of Boards of Directors in the last number of years. And as I said, I’m just so excited to be here at Merit Medical.
So I’m going to take the time this afternoon to cover a brief company history, a little overview of our business, our key products, our go-to-market strategy and what I think is
Be the first to comment